patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). in this survey we detected factor v and viii inhibitor in ten patients with combined deficiency of factors v and viii from north east of iran (khorassan province). it was revealed in our survey that eight patients had both factor v and factor viii inhib...

many investigations have proved relations between abo blood groups with some diseases and factor viii and von willebrand level in plasma. in this study we investigated a relation between abo blood groups and factor viii and ix inhibitors in 102 patients with haemophilia a and 48 patients with haemophilia b. the assay of inhibitor was done by bethesda method. there were no relation between abo b...

background: leukemia inhibitor factor (lif) is a very important pleiotropic cytokine which belongs to interleukin-6 (il-6) family. lif exerts multiple effects on different types of cells and tissues with numerous regulatory effects in vivo and in vitro. it is a lymphoid factor, which performs a number of activities including cholinergic neuron differentia­tion, control of stem cell pluripotency...

background: hemophilia b is a bleeding disorder with a recessive x-linked inheritance pattern, in which the infected individuals have low levels of factor ix in their plasma. affected individuals may have bleeding episodes after trauma or spontaneously considering the plasma level of factor ix. in order to prevent these episodes and to control bleeding, they should use coagulation factor concen...

0

background: factor viii inhibitor is one of the most problems in the treatment of hemophilia. patients with hemophilia who have inhibitors are capable of severe hemorrhage and treatments of these patients are more expensive and more difficult than those patients without inhibitor. the aim of present study was to determine the prevalence of inhibitor and to assess the necessity of screening of t...

conclusions treatment strategies in acquired hemophilia are based on two major objectives. during the acute stage, effective control of bleeding is critical. the ultimate therapeutic goal during the subacute phase is the elimination of the inhibitors targeting factor viii. here, we present this case and will review current literature regarding therapeutic approaches to this rare condition in th...

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...